Pharmacist Mental Health | New Drugs | Patient Safety Podcast 30 credit minutes

Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.

Learning Objectives

Upon successful completion of this course, pharmacists should be able to:
1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.
2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.

Faculty

Rachel Maynard, PharmD

GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

Disclosures:

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

Sara Grady, PharmD, BCPS, BCPP

Professor of Pharmacy Practice, Drake University
Clinical Pharmacist, Broadlawns Medical Center

Disclosures:

Sarah Grady has no relevant financial relationships with ineligible companies to disclose.

Course Details